Sutro Biopharma: Focused on developing next generation antibody drug conjugates (ADCs) and multi-specific antibody-based therapeutics for cancer therapy. The company’s discovery and development efforts are driven by its scalable cell-free protein expression platform (Xpress CF) that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro has two wholly-owned ADCs that are on clinical pathways and two high value collaborations with Celgene and Merck Serono. STRO-001 for multiple myeloma and lymphomas is in Ph 1 and expects initial safety data in mid-2019. IND submission for STRO-002 for ovarian and endometrial cancer in Q4 2018 with the initiation of a Ph 1 trial planned for early 2019.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase l or ll
Disease Space
Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Address:
310 Utah Ave
Suite 150
South San Francisco, CA 94080
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.